Hiroyuki Suzuki

Hiroyuki Suzuki

Auto-generated profile, based on publicly available information

Hiroyuki Suzuki

Department of Chest Surgery, Fukushima Medical University , Fukushima

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
YOYuki Owada-Ozaki
Yuki Owada-Ozaki
SMSatoshi Muto
Satoshi Muto
HTHironori Takagi
Hironori Takagi
TITakuya Inoue
Takuya Inoue
YWYuzuru Watanabe
Yuzuru Watanabe
HSHiroyuki Suzuki
Hiroyuki Suzuki

17 May 2014 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
MHMitsunori Higuchi
Mitsunori Higuchi
HYHiroshi Yaginuma
Hiroshi Yaginuma
AYAtsushi Yonechi
Atsushi Yonechi
RKRyuzo Kanno
Ryuzo Kanno
AOAkio Ohishi
Akio Ohishi
MGMitsukazu Gotoh
Mitsukazu Gotoh
Video-assisted thoracic surgery (VATS) lobectomy is a standard treatment for lung cancer. This study retrospectively compared long-term outcomes after VATS lobectomy versus lobectomy via open thoracotomy for clinical stage IA non-small cell lung cancer (NSCLC).

12 January 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
SMSatoshi Muto
Satoshi Muto
AEAkio Enta
Akio Enta
YMYoshiyuki Maruya
Yoshiyuki Maruya
SISho Inomata
Sho Inomata
HYHikaru Yamaguchi
Hikaru Yamaguchi
HSHiroyuki Suzuki
Hiroyuki Suzuki
Lung cancer is the leading cause of cancer-related deaths worldwide. The standard of care for advanced non-small-cell lung cancer (NSCLC) without driver-gene mutations is a combination of an anti-PD-1/PD-L1 antibody and chemotherapy, or an anti-PD-1/PD-L1 antibody and an anti-CTLA-4 antibody with or without chemotherapy. Although there were fewer cases of disease progression in the early stages of combination treatment than with anti-PD-1/PD-L1 antibodies alone, only approximately half of the patients had a long-term response. Therefore, it is necessary to elucidate the mechanisms of resistance to immune checkpoint inhibitors. Recent reports of such mechanisms include reduced cancer-cell immunogenicity, loss of major histocompatibility complex, dysfunctional tumor-intrinsic interferon-γ signaling, and oncogenic signaling leading to immunoediting. Among these, the Wnt/β-catenin pathway is a notable potential mechanism of immune escape and resistance to immune checkpoint inhibitors. In this review, we will summarize findings on these resistance mechanisms in NSCLC and other cancers, focusing on Wnt/β-catenin signaling. First, we will review the molecular biology of Wnt/β-catenin signaling, then discuss how it can induce immunoediting and resistance to immune checkpoint inhibitors. We will also describe other various mechanisms of immune-checkpoint-inhibitor resistance. Finally, we will propose therapeutic approaches to overcome these mechanisms.

20 May 2019 in Cells
Verified
Journal Article
Open access
PDF file
NTNobuhiko Takahashi
Nobuhiko Takahashi
HHHirotaka Hoshi
Hirotaka Hoshi
AHArisa Higa
Arisa Higa
GHGen Hiyama
Gen Hiyama
HTHirosumi Tamura
Hirosumi Tamura
MTMotoki Takagi
Motoki Takagi
Patient-derived tumor organoids (PDOs) represent a promising preclinical cancer model that better replicates disease, compared with traditional cell culture models. We have established PDOs from various human tumors to accurately and efficiently recapitulate the tissue architecture and function. Molecular targeted therapies with remarkable efficacy are currently in use against various tumors. Thus, there is a need for in vitro functional-potency assays that can be used to test the efficacy of molecular targeted drugs and model complex interactions between immune cells and tumor cells to evaluate the potential for cancer immunotherapy. This study represents an in vitro evaluation of different classes of molecular targeted drugs, including small-molecule inhibitors, monoclonal antibodies, and an antibody-drug conjugate, using lung PDOs. We evaluated epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2) inhibitors using a suitable high-throughput assay system. Next, the antibody-dependent cellular cytotoxicity (ADCC) activity of an anti-HER2 monoclonal antibody was evaluated to visualize the interactions of immune cells with PDOs during ADCC responses. Moreover, an evaluation system was developed for the immune checkpoint inhibitors, nivolumab and pembrolizumab, using PDOs. Our results demonstrate that the in vitro assay systems using PDOs were suitable for evaluating molecular targeted drugs under conditions that better reflect pathological conditions.

11 April 2013 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
HSHiroyuki Suzuki
Hiroyuki Suzuki
MFMitsuro Fukuhara
Mitsuro Fukuhara
TYTakumi Yamaura
Takumi Yamaura
SMSatoshi Mutoh
Satoshi Mutoh
NONaoyuki Okabe
Naoyuki Okabe
MGMitsukazu Gotoh
Mitsukazu Gotoh
Vaccine treatment using multiple peptides derived from multiple proteins is considered to be a promising option for cancer immune therapy, but scientific evidence supporting the therapeutic efficacy of multiple peptides is limited. We conducted phase I trials using a mixture of multiple therapeutic peptide vaccines to evaluate their safety, immunogenicity and clinical response in patients with advanced/recurrent NSCLC. We administered two different combinations of four HLA-A24-restricted peptides. Two were peptides derived from vascular endothelial growth factor receptor 1 (VEGFR1) and 2 (VEGFR2), and the third was a peptide derived from up-regulated lung cancer 10 (URLC10, which is also called lymphocyte antigen 6 complex locus K [LY6K]). The fourth peptide used was derived from TTK protein kinase (TTK) or cell division associated 1 (CDCA1). Vaccines were administered weekly by subcutaneous injection into the axillary region of patients with montanide ISA-51 incomplete Freund’s adjuvant, until the disease was judged to have progressed or patients requested to be withdrawn from the trial. Immunological responses were primarily evaluated using an IFN-gamma ELiSPOT assay. Vaccinations were well tolerated with no severe treatment-associated adverse events except for the reactions that occurred at the injection sites. Peptide-specific T cell responses against at least one peptide were observed in 13 of the 15 patients enrolled. Although no patient exhibited complete or partial responses, seven patients (47%) had stable disease for at least 2 months. The median overall survival time was 398 days, and the 1- and 2-year survival rates were 58.3% and 32.8%, respectively. Peptide vaccine therapy using a mixture of four novel peptides was found to be safe, and is expected to induce strong specific T cell responses. These studies were registered with ClinicalTrials.gov NCT00633724 and NCT00874588 .

1 June 2015 in Lung Cancer
Verified
Journal Article
Closed access
JOJun Osugi
Jun Osugi
TYTakumi Yamaura
Takumi Yamaura
SMSatoshi Muto
Satoshi Muto
NONaoyuki Okabe
Naoyuki Okabe
YMYuki Matsumura
Yuki Matsumura
MGMitsukazu Gotoh
Mitsukazu Gotoh